#37: Lipids, PCSK9, and ezetimibe: Lower is better.
Learn the latest in lipid lowering therapy in this extensive discussion with Dr. Paul S. Jellinger, MD, MACE, Professor of Medicine at the University of Miami and Chair of the writing committee for the American Association of Clinical Endocrinologists (AACE) 2017 Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease (CVD). Topics include ezetimibe, PCSK9, FOURIER trial, statin myopathy, CoQ10, fish oil, fibrates and more. For a more basic discussion of dyslipidemia check out episode #10.
Full show notes are available at http://thecurbsiders.com/podcast
Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com.
Time Stamps
00:00 Intro
03:10 Rapid fire questions
08:15 Dyslipidemia defined
10:26 Classifying dyslipidemia
13:21 Diagnosing Familial Hypercholesterolemia
17:48 A difficult lipid case discussed
22:40 Lp (a), Apo B and LDL particle concentration
28:40 What labs to order
31:31 ACC/AHA versus other risk scores
38:21 IMPROVE-IT
41:35 Non-statin medications discussed
45:05 Hypertriglyceridemia fibrates and fish oil
48:25 How often to check the lipid panel
49:58 Statin Myopathy and CoQ10
54:17 FOURIER, PCSK9 and very low LDLs
59:43 Extreme risk category discussed
62:34 Is plaque regression possible?
64:12 Take home points
67:08 Outro
Tags: assistant, care, cholesterol, doctor, education family, fish oil, foam, foamed, health, hospitalist, hospital, internal, internist, ldl, lipid, medicine, medical, myopathy, nurse, pcsk9, physician, practitioner, primary, statin, resident, student